Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Summary

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.

Timeline

Start

2022-05-03

Primary completion

2023-05-03

Completion

2023-10-12

Outcome

Outcome not reported

Stopped: “Sponsor change”

Drugs

Indications